Sarepta Therapeutics Q1 Revenue Reaches $730.8M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy SRPT?
Reports Q1 revenue $730.8M, consensus $475.01M. "We entered 2026 with clear priorities-stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each," said Doug Ingram, chief executive officer, Sarepta Therapeutics. "Our commercial portfolio has begun to stabilize, supported by expanded field engagement and a growing body of evidence reinforcing the disease-modifying impact of ELEVIDYS, which we believe is positioned to return to growth. At the same time, we are advancing Cohort 8 of the ENDEAVOR study with sirolimus pretreatment to serve our goal of once again making ELEVIDYS available to the non-ambulatory community. Finally, we remain in a position of financial strength, with positive earnings, and continued cash flow generation that enables us to fully fund our pipeline. Our potentially best-in-class clinical-stage siRNA portfolio continues to advance, with encouraging early signals in DM1 and FSHD and multiple upcoming readouts across high-value programs."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to rise
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 19.955
Low
5.00
Averages
20.80
High
45.00
Current: 19.955
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
Sarepta Therapeutics Q1 2026 Earnings Call Insights
- Stable Financial Performance: Sarepta reported total net product revenue of $331 million in Q1 2026, with PMO therapies contributing $229 million and ELEVIDYS $102 million, indicating a gradual recovery in profitability following disruptions in 2025.
- Guidance Reaffirmation: Management reiterated its 2026 net product revenue guidance of $1.2 billion to $1.4 billion, while emphasizing that the recovery of ELEVIDYS demand will be a slow process, reflecting a cautious approach to market dynamics.
- Cash Flow and Investments: As of the end of Q1, Sarepta held approximately $748 million in cash and investments, achieving positive cash flow excluding Arrowhead-related payments, demonstrating the company's ability to fund its pipeline without reliance on equity markets.
- Clinical Progress and Regulation: Sarepta is advancing standard approval applications for VYONDYS and AMONDYS, with a PDUFA date expected in February next year, showcasing the company's efforts to strengthen the regulatory standing of its product portfolio.
See More
Sarepta's Q1 Results Beat Expectations but Shares Drop
- Strong Performance: Sarepta Therapeutics reported Q1 total revenue of $730.8 million, which, despite a 2% year-over-year decline, exceeded market expectations of $475.01 million, demonstrating resilience in revenue generation.
- Adjusted EPS Improvement: The company posted an adjusted earnings per share of $3.16, a significant recovery from a loss of $3.42 in the same quarter last year, and comfortably above the analyst estimate of $1.09, indicating a marked improvement in profitability.
- Decline in Elevidys Sales: Elevidys generated $102 million in net product sales, a sharp drop from $375 million in Q1 2025, primarily due to safety concerns limiting the addressable patient population, which adversely affected the company's core business.
- Future Guidance: Sarepta reiterated its full-year 2026 guidance for total net product revenue between $1.2 billion and $1.4 billion, and despite challenges, CEO Doug Ingram expressed optimism about the stabilization of the company's commercial portfolio and the growth potential of Elevidys.
See More
Sarepta Therapeutics Q1 Results Beat Expectations Despite Stock Decline
- Strong Financial Performance: Sarepta Therapeutics reported a non-GAAP EPS of $3.16 for Q1, beating expectations by $2.11, indicating an improvement in profitability despite a year-over-year revenue decline.
- Revenue Guidance Adjustment: The company projects net product revenues for 2026 to be between $1.2 billion and $1.4 billion, falling short of the consensus estimate of $1.73 billion, reflecting market caution regarding future growth.
- Significant R&D Expense Reduction: R&D expenses for the quarter were $154 million, a substantial decrease from $773.4 million year-over-year, demonstrating effective cost control measures that have positively impacted overall financial health.
- Cash Flow Status: As of the end of the quarter, the company had cash, cash equivalents, restricted cash, and investments totaling $748.3 million, down from $953.8 million on December 31, 2025, indicating a tightening of cash resources.
See More
Sarepta Therapeutics Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Sarepta Therapeutics reported a Q1 non-GAAP EPS of $3.16, beating expectations by $2.11, which reflects a significant enhancement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q1 revenue of $730.8 million, a slight decline of 1.9% year-over-year, yet it surpassed market expectations by $255.79 million, indicating a stable revenue performance in a competitive market.
- Substantial Operating Income: Sarepta's GAAP and non-GAAP operating income for Q1 stood at $358.4 million and $397.7 million, respectively, showcasing successful cost control and operational efficiency, further solidifying its market position.
- siRNA Pipeline Progress: Preliminary Phase 1/2 data for SRP-1001 and SRP-1003 demonstrate dose-dependent drug exposure, early biomarker effects, and favorable tolerability, suggesting potential breakthroughs in the treatment of muscle diseases.
See More
Sarepta Therapeutics to Report Q1 2026 Financial Results
- Earnings Release Schedule: Sarepta Therapeutics is set to announce its Q1 2026 financial results after the Nasdaq Global Market closes on May 6, 2026, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: Following the earnings release, Sarepta will host a conference call at 4:30 p.m. E.T. to discuss the financial results, with phone participants required to register in advance to obtain dial-in information, ensuring smooth communication of important updates.
- Investor Relations Focus: The company emphasizes transparency and investor communication by offering a live webcast and a one-year replay on its investor relations website, aiming to bolster investor confidence and engagement.
- Company Mission and Vision: Sarepta is committed to developing precision genetic medicine for rare diseases, particularly leading in Duchenne muscular dystrophy, showcasing its strong R&D capabilities across muscle, central nervous system, and cardiac diseases.
See More
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
Sarepta Therapeutics Q1 2026 Earnings Call Insights
- Stable Financial Performance: Sarepta reported total net product revenue of $331 million in Q1 2026, with PMO therapies contributing $229 million and ELEVIDYS $102 million, indicating a gradual recovery in profitability following disruptions in 2025.
- Guidance Reaffirmation: Management reiterated its 2026 net product revenue guidance of $1.2 billion to $1.4 billion, while emphasizing that the recovery of ELEVIDYS demand will be a slow process, reflecting a cautious approach to market dynamics.
- Cash Flow and Investments: As of the end of Q1, Sarepta held approximately $748 million in cash and investments, achieving positive cash flow excluding Arrowhead-related payments, demonstrating the company's ability to fund its pipeline without reliance on equity markets.
- Clinical Progress and Regulation: Sarepta is advancing standard approval applications for VYONDYS and AMONDYS, with a PDUFA date expected in February next year, showcasing the company's efforts to strengthen the regulatory standing of its product portfolio.
See More
Sarepta's Q1 Results Beat Expectations but Shares Drop
- Strong Performance: Sarepta Therapeutics reported Q1 total revenue of $730.8 million, which, despite a 2% year-over-year decline, exceeded market expectations of $475.01 million, demonstrating resilience in revenue generation.
- Adjusted EPS Improvement: The company posted an adjusted earnings per share of $3.16, a significant recovery from a loss of $3.42 in the same quarter last year, and comfortably above the analyst estimate of $1.09, indicating a marked improvement in profitability.
- Decline in Elevidys Sales: Elevidys generated $102 million in net product sales, a sharp drop from $375 million in Q1 2025, primarily due to safety concerns limiting the addressable patient population, which adversely affected the company's core business.
- Future Guidance: Sarepta reiterated its full-year 2026 guidance for total net product revenue between $1.2 billion and $1.4 billion, and despite challenges, CEO Doug Ingram expressed optimism about the stabilization of the company's commercial portfolio and the growth potential of Elevidys.
See More
Sarepta Therapeutics Q1 Results Beat Expectations Despite Stock Decline
- Strong Financial Performance: Sarepta Therapeutics reported a non-GAAP EPS of $3.16 for Q1, beating expectations by $2.11, indicating an improvement in profitability despite a year-over-year revenue decline.
- Revenue Guidance Adjustment: The company projects net product revenues for 2026 to be between $1.2 billion and $1.4 billion, falling short of the consensus estimate of $1.73 billion, reflecting market caution regarding future growth.
- Significant R&D Expense Reduction: R&D expenses for the quarter were $154 million, a substantial decrease from $773.4 million year-over-year, demonstrating effective cost control measures that have positively impacted overall financial health.
- Cash Flow Status: As of the end of the quarter, the company had cash, cash equivalents, restricted cash, and investments totaling $748.3 million, down from $953.8 million on December 31, 2025, indicating a tightening of cash resources.
See More
Sarepta Therapeutics Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Sarepta Therapeutics reported a Q1 non-GAAP EPS of $3.16, beating expectations by $2.11, which reflects a significant enhancement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q1 revenue of $730.8 million, a slight decline of 1.9% year-over-year, yet it surpassed market expectations by $255.79 million, indicating a stable revenue performance in a competitive market.
- Substantial Operating Income: Sarepta's GAAP and non-GAAP operating income for Q1 stood at $358.4 million and $397.7 million, respectively, showcasing successful cost control and operational efficiency, further solidifying its market position.
- siRNA Pipeline Progress: Preliminary Phase 1/2 data for SRP-1001 and SRP-1003 demonstrate dose-dependent drug exposure, early biomarker effects, and favorable tolerability, suggesting potential breakthroughs in the treatment of muscle diseases.
See More
Sarepta Therapeutics to Report Q1 2026 Financial Results
- Earnings Release Schedule: Sarepta Therapeutics is set to announce its Q1 2026 financial results after the Nasdaq Global Market closes on May 6, 2026, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: Following the earnings release, Sarepta will host a conference call at 4:30 p.m. E.T. to discuss the financial results, with phone participants required to register in advance to obtain dial-in information, ensuring smooth communication of important updates.
- Investor Relations Focus: The company emphasizes transparency and investor communication by offering a live webcast and a one-year replay on its investor relations website, aiming to bolster investor confidence and engagement.
- Company Mission and Vision: Sarepta is committed to developing precision genetic medicine for rare diseases, particularly leading in Duchenne muscular dystrophy, showcasing its strong R&D capabilities across muscle, central nervous system, and cardiac diseases.
See More
